Litcius/Paper detail

YAP in pancreatic cancer: oncogenic role and therapeutic strategy

Wenhao Mao, Jia Mai, Hui Peng, Junhu Wan, Ting Sun

2020Theranostics53 citationsDOIOpen Access PDF

Abstract

Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), remains a fatal disease with few efficacious treatments. The Hippo signaling pathway, an evolutionarily conserved signaling module, plays critical roles in tissue homeostasis, organ size control and tumorigenesis. The transcriptional coactivator yes-associated protein (YAP), a major downstream effector of the Hippo pathway, is associated with various human cancers including PDAC. Considering its importance in cancer, YAP is emerging as a promising therapeutic target. In this review, we summarize the current understanding of the oncogenic role and regulatory mechanism of YAP in PDAC, and the potential therapeutic strategies targeting YAP.

Topics & Concepts

Pancreatic cancerCancer researchPancreatic ductal adenocarcinomaCancerMedicineInternal medicineHippo pathway signaling and YAP/TAZUbiquitin and proteasome pathwaysLipid metabolism and biosynthesis
YAP in pancreatic cancer: oncogenic role and therapeutic strategy | Litcius